$TLSI
TriSalus Life Sciences, Inc. Stock $tlsi

$tlsi Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000182666724000039 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$7.349M	$7.364M	$4.612M
YoY Change	41.52%	59.67%
Cost Of Revenue	$1.004M	$912.0K	$772.0K
YoY Change	70.46%	18.13%
Gross Profit	$6.345M	$6.452M	$3.840M
YoY Change	37.81%	68.02%
Gross Profit Margin	86.34%	87.62%	83.26%
Selling, General & Admin	$10.87M	$9.960M	$8.412M
YoY Change	-20.77%	18.4%	2818.1%
% of Gross Profit	171.24%	154.37%	219.06%
Research & Development	$4.219M	$4.666M	$6.862M
YoY Change	-54.96%	-32.0%
% of Gross Profit	66.49%	72.32%	178.7%
Depreciation & Amortization	$169.0K	$194.0K	$334.0K
YoY Change	1.81%	-41.92%
% of Gross Profit	2.66%	3.01%	8.7%
Operating Expenses	$15.08M	$14.63M	$15.27M
YoY Change	-34.65%	-4.24%	5198.5%
Operating Profit	-$8.739M	-$8.174M	-$1.430M
YoY Change	-52.7%	471.61%	396.05%
Interest Expense	-$984.0K	$877.0K	-$3.572M
YoY Change	-24700.0%	-124.55%	-1235.01%
% of Operating Profit
Other Income/Expense, Net	-$13.00K	-$44.00K	$477.7K
YoY Change	0.0%	-109.21%	-80.0%
Pretax Income	-$2.402M	-$4.325M	-$952.3K
YoY Change	86.78%	354.16%	-139.44%
Income Tax	-$3.000K	$7.000K	$42.72K
% Of Pretax Income
Net Earnings	-$2.399M	-$4.332M	-$995.0K
YoY Change	86.55%	335.36%	-141.7%
Net Earnings / Revenue	-32.64%	-58.83%	-21.58%
Basic Earnings Per Share	-$0.12	-$0.21	-$35.84
Diluted Earnings Per Share	-$0.12	-$0.21	-$0.61
COMMON SHARES
Basic Shares Outstanding	29.31M shares	26.76M shares	446.3K shares
Diluted Shares Outstanding	26.50M shares	23.90M shares	446.3K shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.29M	$16.48M	$3.904M
YoY Change	-47.21%	322.16%	5543.25%
Cash & Equivalents	$11.29M	$16.48M	$104.0K
Short-Term Investments
Other Short-Term Assets	$3.609M	$3.311M	$4.859M
YoY Change	21.23%	-31.86%	2363.37%
Inventory	$3.999M	$3.443M	$1.522M
Prepaid Expenses	$3.609M	$3.311M	$57.48K
Receivables	$4.912M	$4.706M	$2.094M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$23.81M	$27.94M	$161.5K
YoY Change	-18.02%	17205.86%	-39.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.818M	$1.830M	$3.207M
YoY Change	-4.16%	-42.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$424.0K	$424.0K	$367.0K
YoY Change	15.53%	15.53%	-99.85%
Total Long-Term Assets	$3.669M	$4.490M	$12.08M
YoY Change	-18.7%	-62.82%	-95.18%
TOTAL ASSETS
Total Short-Term Assets	$23.81M	$27.94M	$161.5K
Total Long-Term Assets	$3.669M	$4.490M	$12.08M
Total Assets	$27.48M	$32.43M	$12.24M
YoY Change	-18.11%	165.01%	-95.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.446M	$1.976M	$4.297M
YoY Change	-23.85%	-54.01%	461.52%
Accrued Expenses	$7.877M	$9.407M	$9.490M
YoY Change	19.35%	-0.87%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.918M	$12.00M	$6.031M
YoY Change	6.59%	98.91%	247.14%
LONG-TERM LIABILITIES
Long-Term Debt	$21.68M	$21.29M	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$16.32M	$23.30M	$1.672M
YoY Change	3.51%	1293.36%	-82.96%
Total Long-Term Liabilities	$21.68M	$21.29M	$1.672M
YoY Change	37.53%	1173.09%	-83.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.918M	$12.00M	$6.031M
Total Long-Term Liabilities	$21.68M	$21.29M	$1.672M
Total Liabilities	$47.91M	$56.58M	$15.31M
YoY Change	91.13%	269.51%	27.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$269.4M	-$265.9M	-$15.12M
YoY Change	26.58%	1658.71%
Common Stock	$3.000K	$2.000K
YoY Change	50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$20.43M	-$24.15M	-$15.12M
YoY Change
Total Liabilities & Shareholders Equity	$27.48M	$32.43M	$12.24M
YoY Change	-18.11%	165.01%	-95.12%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$2.399M	-$4.332M	-$995.0K
YoY Change	86.55%	335.36%	-141.7%
Depreciation, Depletion And Amortization	$169.0K	$194.0K	$334.0K
YoY Change	1.81%	-41.92%
Cash From Operating Activities	-$10.85M	-$13.42M	-$19.04M
YoY Change	-49.45%	-29.5%	2632.54%
INVESTING ACTIVITIES
Capital Expenditures	$169.0K	$60.00K	$38.00K
YoY Change	-5.06%	57.89%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$164.0K
YoY Change	-100.0%	-100.0%	105.0%
Cash From Investing Activities	-$169.0K	-$60.00K	$126.0K
YoY Change	-87.17%	-147.62%	57.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.823M	25.99M	13.41M
YoY Change	-85.53%	93.79%	2012.28%
NET CHANGE
Cash From Operating Activities	-10.85M	-13.42M	-19.04M
Cash From Investing Activities	-169.0K	-60.00K	126.0K
Cash From Financing Activities	5.823M	25.99M	13.41M
Net Change In Cash	-5.193M	12.51M	-5.500M
YoY Change	-129.71%	-327.47%	-30236.99%
FREE CASH FLOW
Cash From Operating Activities	-$10.85M	-$13.42M	-$19.04M
Capital Expenditures	$169.0K	$60.00K	$38.00K
Free Cash Flow	-$11.02M	-$13.48M	-$19.08M
YoY Change	-49.08%	-29.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	59000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2660000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2064000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24289000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19739000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16831000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4154000	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	222437000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-25938000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25725000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13821000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-25938000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2763000	usd
CY2024Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1664000	usd
CY2024Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	351000	usd
CY2024Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	386000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1113000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1127000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	466000	usd
CY2024Q2	us-gaap	Assets Assets	32431000	usd
CY2023Q4	us-gaap	Assets Assets	25725000	usd
CY2024Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1976000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3391000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9407000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10556000	usd
CY2024Q2	tlsi	Lease Liability Current LeaseLiabilityCurrent	323000	usd
CY2023Q4	tlsi	Lease Liability Current LeaseLiabilityCurrent	351000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	291000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	389000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11997000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14687000	usd
CY2023Q4	tlsi	Common Stock Share Price Market Price Number Of Consecutive Trading Days CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays	P3D
CY2023Q3	tlsi	Preferred Stock Number Of Trading Days Volume Weighted Average Price PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice	P10D
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	424000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21286000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2024Q2	tlsi	Revenue Base Redemption Liability RevenueBaseRedemptionLiability	715000	usd
CY2023Q4	tlsi	Revenue Base Redemption Liability RevenueBaseRedemptionLiability	0	usd
CY2024Q2	tlsi	Lease Liability Noncurrent LeaseLiabilityNoncurrent	1154000	usd
CY2023Q4	tlsi	Lease Liability Noncurrent LeaseLiabilityNoncurrent	1244000	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	8931000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	18632000	usd
CY2024Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	12497000	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	17100000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	56580000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	51663000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	10.00
CY2024Q2	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	10.00
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4015002	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	4015002	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26413213	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26413213	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	241777000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-265928000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-248377000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-24149000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32431000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7596000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1883000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1434000	usd
	us-gaap	Gross Profit GrossProfit	11938000	usd
	us-gaap	Gross Profit GrossProfit	6162000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10523000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12504000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	12691000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6741000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8583000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8472000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19859000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21555000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	189000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	71000	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	877000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	4000	usd
	us-gaap	Interest Expense InterestExpense	880000	usd
	us-gaap	Interest Expense InterestExpense	9000	usd
	tlsi	Gain Loss On Equity Issuance GainLossOnEquityIssuance	0	usd
	tlsi	Gain Loss On Equity Issuance GainLossOnEquityIssuance	-4189000	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	0	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	0	usd
	tlsi	Gain Loss On Change In Fair Value Of Warrants And Other Liabilities GainLossOnChangeInFairValueOfWarrantsAndOtherLiabilities	-6495000	usd
	tlsi	Gain Loss On Change In Fair Value Of Warrants And Other Liabilities GainLossOnChangeInFairValueOfWarrantsAndOtherLiabilities	3491000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-9701000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-197000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-43000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17541000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22234000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17551000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22242000	usd
	us-gaap	Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	0	usd
	us-gaap	Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	2981000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1602000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19153000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25223000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-35.84
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-35.84
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-59.79
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-59.79
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	446287	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	446287	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	421861	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	421861	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1086000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3141000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-13219000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-34923000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1275000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3602000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	11923000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1699000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-4332000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-24149000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-176330000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	74000	usd
CY2023Q1	us-gaap	Preferred Stock Convertible Down Round Feature Increase Decrease In Equity Amount1 PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-8268000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-184473000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	16000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	69000	usd
CY2023Q2	us-gaap	Preferred Stock Convertible Down Round Feature Increase Decrease In Equity Amount1 PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1	0	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-13974000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-198363000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-198363000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17551000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22242000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	382000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	334000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	152000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-6921000	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	3491000	usd
	tlsi	Gain Loss On Change In Fair Value Of Revenue Base Redemption And Warrant Liability GainLossOnChangeInFairValueOfRevenueBaseRedemptionAndWarrantLiability	426000	usd
	tlsi	Gain Loss On Change In Fair Value Of Revenue Base Redemption And Warrant Liability GainLossOnChangeInFairValueOfRevenueBaseRedemptionAndWarrantLiability	0	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-9701000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	151000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
	tlsi	Gain Loss On Equity Issuance GainLossOnEquityIssuance	0	usd
	tlsi	Gain Loss On Equity Issuance GainLossOnEquityIssuance	-4189000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2361000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	142000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-18000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-60000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	267000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1152000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	537000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	899000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	51000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2025000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	266000	usd
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	-43000	usd
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	0	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-170000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	126000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	38000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	66000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-126000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-104000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	9184000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6743000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5126000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2593000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	25000000	usd
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	43000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	43000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	66000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29119000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14333000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4704000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5510000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12127000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9664000	usd
	tlsi	Warrants Issued In Connection With Debt Value WarrantsIssuedInConnectionWithDebtValue	811000	usd
	tlsi	Warrants Issued In Connection With Debt Value WarrantsIssuedInConnectionWithDebtValue	0	usd
	tlsi	Revenue Base Redemption Feature In Connection With Debt Value RevenueBaseRedemptionFeatureInConnectionWithDebtValue	729000	usd
	tlsi	Revenue Base Redemption Feature In Connection With Debt Value RevenueBaseRedemptionFeatureInConnectionWithDebtValue	0	usd
	tlsi	Warrants Issued In Connection With Issuance Of Preferred Stock Value WarrantsIssuedInConnectionWithIssuanceOfPreferredStockValue	0	usd
	tlsi	Warrants Issued In Connection With Issuance Of Preferred Stock Value WarrantsIssuedInConnectionWithIssuanceOfPreferredStockValue	14701000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	90000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	tlsi	Class Of Warrant Or Right Transfer Of Warrant To Preferred Stock ClassOfWarrantOrRightTransferOfWarrantToPreferredStock	0	usd
	tlsi	Class Of Warrant Or Right Transfer Of Warrant To Preferred Stock ClassOfWarrantOrRightTransferOfWarrantToPreferredStock	12082000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2023 (the "Closing Date"), TriSalus Life Sciences, Inc., a Delaware corporation (the “Company,” “TriSalus,” “we,” “us”), formerly known as MedTech Acquisition Corporation (“MTAC”), consummated the previously announced merger pursuant to the Agreement and Plan of Merger, dated as of November 11, 2022, as amended by that certain First Amendment to Agreement and Plan of Merger, dated as of April 4, 2023, the Second Amendment to Agreement and Plan of Merger, dated as of May 13, 2023, and the Third Amendment to Agreement and Plan of Merger, dated as of July 5, 2023 (as amended, the “Merger Agreement”), by and between MTAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of MTAC (“Merger Sub”) and TriSalus Operating Life Sciences, Inc. (formerly known as TriSalus Life Sciences, Inc.), a Delaware corporation (“Legacy TriSalus”), whereby Merger Sub merged with and into Legacy TriSalus with the separate corporate existence of Merger Sub ceasing (the “Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Business Combination”) and TriSalus Life Sciences, Inc. becoming the surviving company. The closing of the Business Combination is herein referred to as “the Closing.” In connection with the consummation of the Merger, on August 10, 2023, Legacy TriSalus changed its name from TriSalus Life Sciences, Inc. to TriSalus Operating Life Sciences, Inc., and MTAC changed its name from MedTech Acquisition Corporation to TriSalus Life Sciences, Inc., the surviving company ("New TriSalus”). As further described in Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(3) Business Combination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Legacy TriSalus was deemed to be the accounting acquirer and predecessor company in the Business Combination. Thus, the prior periods presented in these condensed consolidated financial statements are of Legacy TriSalus.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of the Business</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dedicated to the research, development, and commercialization of an innovative drug delivery technology platform and an immuno-oncology therapeutic, aimed at improving outcomes for patients with difficult-to-treat liver and pancreatic cancers. Our advanced technology is designed for use by interventional radiologists to enhance the delivery of therapeutics and improve patient outcomes. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our cutting-edge Pressure Enabled Drug Delivery (PEDD™) infusion systems, which optimize therapeutic delivery for hepatocellular carcinoma, pancreatic cancer, and other solid liver tumors. Additionally, we are developing nelitolimod, a TLR9 agonist with the potential to bolster the immune system's response. We are developing and marketing a product line — PEDD infusion systems, in use today—and we are developing a drug product candidate, nelitolimod, which has demonstrated a potential to enhance immune system response, when delivered via PEDD, in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. The combination of our PEDD technology with nelitolimod is focused on solving the two main barriers in the tumor microenvironment that inhibits the success of systemic therapies. The first barrier (mechanical) is comprised of high intratumoral pressure within tumors that limits drug uptake and the second barrier (biological) is the reversal of intratumoral immunosuppression. Our PEDD with SmartValve™ is the only technology designed to work in synchrony with the cardiac cycle to open collapsed vessels in the tumor to enable deeper perfusion and improve therapeutic drug delivery in tumors with high intratumoral pressure. PEDD with SmartValve has been shown in prospective and retrospective clinical studies and in multiple pre-clinical models to improve therapy uptake and tumor response. nelitolimod has a dual mechanism of action in solid tumors which includes the alteration of the tumor microenvironment by reducing immunosuppressive myeloid derived suppressor cells while simultaneously activating immune response and recruiting T-cells to the tumor, allowing checkpoint inhibitors to work more effectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TriNav™ is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. Current sales consist of the TriNav Infusion System, introduced in 2020, and a family of related guiding catheters. In 2020, we gained transitional pass-through payments (“TPT”) approval from the Centers for Medicare & Medicaid Services (“CMS”), which allows hospitals to cover the cost of using TriNav. The approval expired at the end of 2023. On June 1, 2023, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we applied for a new technology APC code with CMS. In December 2023, CMS granted a New Technology Healthcare Common Procedure Coding System ("HCPCS") code for both mapping and therapeutic procedures involving TriNav. This new code, HCPCS C9797, has been assigned to the Ambulatory Payment Classification ("APC") code 5194 - Level 4 Endovascular procedures. The new code became effective on January 1, 2024, and may be reported by hospital outpatient departments and ambulatory surgical centers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the full potential of our technology can be realized through the combination of our drug delivery technology with immune-oncology drugs. In July 2020, we acquired our first immune-oncology drug, nelitolimod, and began clinical development of nelitolimod for treatment of liver and pancreatic cancers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have funded operations to date principally with proceeds from the sale of preferred stock, from the issuance of debt and convertible debt, and the closing of the Business Combination. Since inception of the Company in 2009 through June 30, 2024, we have issued for cash $164,364 of preferred stock (of which $36,854 was raised at the closing of the Business Combination, including issuance of Series A convertible preferred stock), which, along with $7,315 from common stock and $57,466 from convertible notes and warrants, has funded our accumulated deficit of $265,928. During the six months ended June 30, 2024, we raised $6,743 in cash through the sale of common stock under the Standby Equity Purchase Agreement, which we entered into with YA II PN, Ltd. ("Yorkville") on October 2, 2023 (the "SEPA") and $12 from the exercise of stock options. See Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(13) Standby Equity Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for discussion of the SEPA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2024 (the "OrbiMed Closing Date"), we entered into a Credit Agreement (the "Credit Agreement") with OrbiMed Royalty & Credit Opportunities IV, LP ("OrbiMed"), a healthcare investment firm. Under the terms of the Credit Agreement, we may borrow up to $50,000, of which we immediately drew $25,000, before expenses. The remaining debt is available in two increments of $10,000 and $15,000, subject to the achievement of certain revenue targets. See Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(14) Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, we had cash, cash equivalents, and restricted cash of $16,831. The Company is still in its early stage, has a history of recurring operating losses, has yet to generate revenues sufficient to create positive cash flow and has an accumulated deficit of $265,928 as of June 30, 2024. We expect that our existing cash and cash equivalents will not be sufficient to fund our projected liquidity requirements for the next 12 months from the issuance date of the financial statements. If we are able to achieve certain targets specified in the Credit Agreement and are then able to draw the remainder of the funds available, and if market conditions allow us to sell additional shares under the SEPA, we believe we can fund our operations through the end of 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements, Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period. In evaluating our ability to continue as a going concern, management projected our cash flow sources and needs and evaluated the conditions and events that could raise substantial doubt about our ability to continue as a going concern within one year after the date that these condensed consolidated financial statements were issued. Management’s plans to address the conditions and events have considered our current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of these condensed consolidated financial statements as to whether we have the ability to fund future operations and meet our obligations as they become due in the normal course of business.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to fund future operations and to continue the execution of our long-term business plan and strategy, including our transformation into a therapeutics company, will require that we raise additional capital through a combination of collaborations, strategic alliances and licensing arrangements, and issuance of additional equity and/or debt. As described in Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(13) Standby Equity Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have the right but not the obligation to sell up to $30,000 of our Common Stock at our request under the SEPA, subject to terms and conditions specified in the agreement. During the six months ended June 30, 2024, we sold 750,000 shares of common stock under the SEPA, raising $6,743. In addition, as described in Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(14) Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in April 2024, we entered into a secured loan for up to $50,000, of which we immediately drew $25,000, before expenses. Outside of these agreements, there can be no assurance that we will be able to raise such additional financing or, if available, that such financing can be obtained on satisfactory terms. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring clinical trials and capital expenditures, and reducing other operating costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current operating plan, which is in part determined based on our most recent results and trends, along with the items noted above, causes substantial doubt to exist about our ability to continue as a going concern and management’s plans do not alleviate the existence of substantial doubt. Our financial statements have been prepared assuming we will continue as a going concern, which contemplates the continuity of normal business activities and realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various risks and uncertainties frequently encountered by companies in the early stages of growth, particularly companies in the rapidly evolving market for medical technology-based and pharmaceutical products and services. Such risks and uncertainties include, but are not limited to, a limited operating history, need for additional capital, a volatile business and technological environment, the process to test and obtain approval to market the candidate pharmaceutical, an evolving business model, and demand for our products. To address these risks, we must, among other things, gain access to capital in sufficient amounts and on acceptable terms, maintain and increase our customer base, implement and successfully execute our business strategy, develop the candidate pharmaceutical, continue to enhance our technology, provide superior customer service, and attract, retain, and motivate qualified personnel. There can be no guarantee that we will succeed in addressing such risks.</span></div>
CY2023Q3	tlsi	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	36854000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7315000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-265928000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16831000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-265928000	usd
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	750000	shares
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	6743000	usd
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q4	tlsi	Standby Equity Purchase Agreement Term StandbyEquityPurchaseAgreementTerm	P24M
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.91pt">Use of Estimates</span>The preparation of the condensed consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of earnout, warrant and tranche liabilities, and the valuation allowance on deferred tax assets.
CY2023Q3	tlsi	Proceeds From Reverse Recapitalization Transaction ProceedsFromReverseRecapitalizationTransaction	42854000	usd
CY2023Q3	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	2704000	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	40150000	usd
CY2023Q3	tlsi	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	36854000	usd
CY2023Q3	tlsi	Reverse Recapitalization Transaction Costs Incurred ReverseRecapitalizationTransactionCostsIncurred	6069000	usd
CY2023Q3	tlsi	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	1742000	usd
CY2023Q3	tlsi	Reverse Recapitalization Transaction Costs Paid ReverseRecapitalizationTransactionCostsPaid	4327000	usd
CY2023Q3	tlsi	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.02471853	shares
CY2023Q3	tlsi	Stock Converted Reverse Recapitalization StockConvertedReverseRecapitalization	21999886	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14266605	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	28927000	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	8931000	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	16916000	usd
	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-6712000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements	-11923000	usd
CY2024Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	11705000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16481000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11777000	usd
CY2024Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	350000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	350000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16831000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12127000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	350000	usd
CY2024Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	350000	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	901000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	607000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2542000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2055000	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	117000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	3443000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2545000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	25000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	51000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	51000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	51000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	51000	usd
CY2024Q2	tlsi	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	884000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1113000	usd
CY2024Q2	tlsi	Accrued Clinical Trial Liability Current AccruedClinicalTrialLiabilityCurrent	3706000	usd
CY2023Q4	tlsi	Accrued Clinical Trial Liability Current AccruedClinicalTrialLiabilityCurrent	3115000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2790000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	3736000	usd
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	327000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	557000	usd
CY2024Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	500000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	0	usd
CY2024Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	37000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	31000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9407000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10556000	usd
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	28927000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	18632000	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	8931000	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14345917	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14215112	shares
	tlsi	Class Of Warrant Or Right Threshold Number Of Days For Warrants To Be Transferable ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable	P30D
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1699000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	tlsi	Standby Equity Purchase Agreement Term StandbyEquityPurchaseAgreementTerm	P24M
CY2023Q4	tlsi	Standby Equity Purchase Agreement Maximum Allowable Percentage Of Outstanding Common Stock StandbyEquityPurchaseAgreementMaximumAllowablePercentageOfOutstandingCommonStock	0.1999
CY2024Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	400000	shares
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	750000	shares
CY2024Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	3602000	usd
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	6743000	usd
CY2024Q2	tlsi	Debt Instrument Paid In Kind Interest Term DebtInstrumentPaidInKindInterestTerm	P15M
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2593000	usd
CY2024Q2	tlsi	Warrant Liability WarrantLiability	811000	usd
CY2024Q2	tlsi	Revenue Base Redemption Feature Amount RevenueBaseRedemptionFeatureAmount	729000	usd
CY2024Q2	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	445000	usd
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	25000000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2593000	usd
CY2024Q2	tlsi	Revenue Base Redemption Feature Amount RevenueBaseRedemptionFeatureAmount	729000	usd
CY2024Q2	tlsi	Warrant Liability WarrantLiability	811000	usd
CY2024Q2	us-gaap	Preferred Stock Capital Shares Reserved For Future Issuance PreferredStockCapitalSharesReservedForFutureIssuance	5984998	shares
CY2024Q2	tlsi	Preferred Stock Dividends Undeclared Cumulative Dividends PreferredStockDividendsUndeclaredCumulativeDividends	2860000	usd
CY2023Q3	tlsi	Preferred Stock Automatic Conversion Period PreferredStockAutomaticConversionPeriod	P4Y
CY2023Q3	tlsi	Preferred Stock Conversion Price Automatic Reset Duration First Reset PreferredStockConversionPriceAutomaticResetDurationFirstReset	P18M
CY2023Q3	tlsi	Preferred Stock Conversion Price Automatic Reset Duration Second Reset PreferredStockConversionPriceAutomaticResetDurationSecondReset	P47M
CY2023Q3	tlsi	Preferred Stock Conversion Price Floor PreferredStockConversionPriceFloor	2.10
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	25237155000	usd
	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	0	usd
CY2024Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	25237155000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	49504834	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20161418	shares
	tlsi	Number Of Equity Incentive Plans NumberOfEquityIncentivePlans	2	plan
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	9523627	shares
CY2024Q2	tlsi	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding	5411058	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4112569	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	2385694	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	927	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1307613	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.11
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1
CY2024Q1	tlsi	Common Stock Period Increase Decrease In Capital Shares Reserved For Future Issuance CommonStockPeriodIncreaseDecreaseInCapitalSharesReservedForFutureIssuance	954278	shares
CY2024Q2	tlsi	Lessee Number Of Operating Leases LesseeNumberOfOperatingLeases	4	lease

Files In Submission

Name	View Source	Status
0001826667-24-000039-index-headers.html	Edgar Link	pending
0001826667-24-000039-index.html	Edgar Link	pending
0001826667-24-000039.txt	Edgar Link	pending
0001826667-24-000039-xbrl.zip	Edgar Link	pending
ex102-westminsterlease_2nd.htm	Edgar Link	pending
ex311ceo302certificationma.htm	Edgar Link	pending
ex312cfo302certificationse.htm	Edgar Link	pending
ex321ceo906certificationma.htm	Edgar Link	pending
ex322cfo906certificationse.htm	Edgar Link	pending
ex47-descriptionofsecuriti.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tlsi-20240630.htm	Edgar Link	pending
tlsi-20240630.xsd	Edgar Link	pending
tlsi-20240630_cal.xml	Edgar Link	unprocessable
tlsi-20240630_def.xml	Edgar Link	unprocessable
tlsi-20240630_lab.xml	Edgar Link	unprocessable
tlsi-20240630_pre.xml	Edgar Link	unprocessable
tlsi-20240630_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TLSI
TriSalus Life Sciences, Inc. Stock $tlsi

2024 Q3 Form 10-Q Financial Statement

#000182666724000039 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TLSI TriSalus Life Sciences, Inc. Stock $tlsi

2024 Q3 Form 10-Q Financial Statement

#000182666724000039 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TLSI
TriSalus Life Sciences, Inc. Stock $tlsi